14.64

0.07% 0.010

After Hours: 14.64

Olema Pharmaceuticals Inc (OLMA)

Overview News Price History Option Chain Financials Discussions Forecast

Olema Pharmaceuticals Inc stock is traded at $14.64, with a volume of 673.52K. It is up +0.07% in the last 24 hours and down -2.79% over the past month. Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Previous Close:

$14.63

Open:

$14.82

24h Volume:

673.52K

Relative Volume:

0.45

Market Cap:

$1.28B

Revenue:

Net Income/Loss:

$-162.45M

P/E Ratio:

-7.8515

EPS:

-1.8646

Net Cash Flow:

$-146.72M

1W Performance:

+0.34%

1M Performance:

-2.79%

6M Performance:

+84.15%

1Y Performance:

+163.31%

1-Day Range:

$14.29

$15.12

1-Week Range:

$13.98

$15.12

52-Week Range:

$3.89

$36.26

Olema Pharmaceuticals Inc Stock (OLMA) Company Profile

Name

Olema Pharmaceuticals Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(415) 651-3316

Address

780 BRANNAN STREET, SAN FRANCISCO

Employee

131

Twitter

Next Earnings Date

2026-05-12

Latest SEC Filings

OLMA's Discussions on Twitter

Compare OLMA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OLMA Olema Pharmaceuticals Inc	14.64	1.28B	0	-162.45M	-146.72M	-1.8646
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-26	Initiated	Wolfe Research	Peer Perform
Mar-19-26	Resumed	Jefferies	Buy
Feb-11-26	Initiated	Stifel	Buy
Jan-07-26	Initiated	Piper Sandler	Overweight
Oct-08-25	Initiated	Guggenheim	Buy
Aug-12-25	Reiterated	Citigroup	Buy
Apr-02-24	Initiated	Goldman	Buy
Jan-30-24	Initiated	Citigroup	Buy
Jul-21-23	Initiated	Oppenheimer	Outperform
May-05-23	Initiated	CapitalOne	Overweight
Feb-22-23	Initiated	Credit Suisse	Outperform
Jul-06-22	Resumed	Canaccord Genuity	Buy
Jun-09-22	Upgrade	H.C. Wainwright	Neutral → Buy
Feb-28-22	Initiated	H.C. Wainwright	Neutral
Dec-07-21	Resumed	Cowen	Outperform
Dec-14-20	Initiated	Canaccord Genuity	Buy
Dec-14-20	Initiated	Cowen	Outperform
Dec-14-20	Initiated	JP Morgan	Overweight
Dec-14-20	Initiated	Jefferies	Buy

View All

Olema Pharmaceuticals Inc Stock (OLMA) Latest News

01:36 AM

Olema Pharmaceuticals (OLMA) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat

01:36 AM

May 04, 2026

Olema Pharmaceuticals seeks senior director to drive breast cancer marketing strategy - Traders Union

May 04, 2026

Five new Olema hires receive stock options at $14.32 a share - Stock Titan

May 04, 2026

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 04, 2026

May 03, 2026

Olema Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

May 03, 2026

Olema Adds Deal Veteran Prakash Raman To Guide Oncology Partnerships - Sahm

May 03, 2026

May 02, 2026

Olema Pharmaceuticals, Inc. Announces New Lease Agreement and Provides Company Information – Form 8-K Filing - Minichart

May 02, 2026

Jennison Associates LLC Takes Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat

May 02, 2026

Pictet Asset Management Holding SA Trims Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat

May 02, 2026

May 01, 2026

Olema Pharmaceuticals Signs New Headquarters Lease at Oyster Point - TipRanks

May 01, 2026

Olema Pharmaceuticals (NASDAQ: OLMA) inks 7-year HQ lease with $18.5M base rent - Stock Titan

May 01, 2026

OLMA Forecast, Price Target & Analyst Ratings | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill

May 01, 2026

Apr 29, 2026

Olema Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Raman Prakash - Moomoo

Apr 29, 2026

Olema (NASDAQ: OLMA) director granted 27,061 stock options - Stock Titan

Apr 29, 2026

Olema Pharmaceuticals Adds Veteran Director to Support Growth - TipRanks

Apr 29, 2026

Olema Pharmaceuticals | 3: Initial statement of beneficial ownership of securities- Raman Prakash - Moomoo

Apr 29, 2026

New Olema (OLMA) director files initial insider ownership report - Stock Titan

Apr 29, 2026

[ARS] Olema Pharmaceuticals, Inc. SEC Filing - Stock Titan

Apr 29, 2026

Executive pay and board seats on ballot at Olema (NASDAQ: OLMA) 2026 meeting - Stock Titan

Apr 29, 2026

[8-K] Olema Pharmaceuticals, Inc. Reports Material Event - Stock Titan

Apr 29, 2026

Olema Pharmaceuticals appoints Prakash Raman to board By Investing.com - Investing.com Nigeria

Apr 29, 2026

Olema Pharmaceuticals appoints Prakash Raman to board - Investing.com

Apr 29, 2026

Prakash Raman named to Olema Pharmaceuticals board - Traders Union

Apr 29, 2026

Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors - Caledonian Record

Apr 29, 2026

Apr 27, 2026

Olema Pharmaceuticals (OLMA) loses 33.4% in 4 weeks, here's why a trend reversal may be around the corner - MSN

Apr 27, 2026

Wall Street Zen Upgrades Olema Pharmaceuticals (NASDAQ:OLMA) to "Sell" - MarketBeat

Apr 27, 2026

Apr 23, 2026

Olema Pharmaceuticals seeks lead senior medical writer to strengthen oncology portfolio - Traders Union

Apr 23, 2026

Apr 22, 2026

OLMA (Olema Pharmaceuticals Inc.) posts narrow Q4 2025 EPS beat, sending shares up two percent in daily trading.Consensus Forecast - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 22, 2026

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Apr 22, 2026

Apr 21, 2026

Olema Pharmaceuticals (OLMA) to Showcase Phase 1 Study Results a - GuruFocus

Apr 21, 2026

Olema brings first human OP-3136 cancer trial results to ASCO - Stock Titan

Apr 21, 2026

Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting - marketscreener.com

Apr 21, 2026

Jim Cramer on Olema Pharmaceuticals: "Too risky for me" - MSN

Apr 21, 2026

Apr 20, 2026

OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results - MSN

Apr 20, 2026

Olema Pharmaceuticals expands workforce to drive oncology innovation - Traders Union

Apr 20, 2026

Can Olema Pharmaceuticals (OLMA) stock keep rising today (Slight Gain) 2026-04-20Community Watchlist - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

Piper Sandler Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Apr 20, 2026

Olema Pharmaceuticals (OLMA) Is Up 5.6% After Preclinical Data Highlight Deeper ER Blockade Potential - Sahm

Apr 20, 2026

Apr 19, 2026

A Look At Olema Pharmaceuticals (OLMA) Valuation After New Preclinical Breast Cancer Data - Sahm

Apr 19, 2026

Olema Pharmaceuticals (NASDAQ:OLMA) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat

Apr 19, 2026

Apr 18, 2026

Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting - Sahm

Apr 18, 2026

Olema Pharmaceuticals (OLMA) Stock: Why It Could Break Down (Smart Money Flows) 2026-04-18 - Cổng thông tin điện tử tỉnh Lào Cai

Apr 18, 2026

Apr 17, 2026

Olema Pharmaceuticals (OLMA) Unveils New Data on Palazestrant - GuruFocus

Apr 17, 2026

Olema Pharmaceuticals unveils new preclinical data ahead of AACR2026 presentation - Traders Union

Apr 17, 2026

Apr 16, 2026